Key result
Doxorubicin-based chemotherapy for aggressive non-Hodgkin lymphoma markedly increased the long-term risk of chronic heart failure compared to the general population (SIR 5.4; 95% CI 4.1-6.9).
Why the study?
Does doxorubicin-based chemotherapy for aggressive NHL increase the long-term risk of cardiovascular disease compared to the general population?
Population
476 Dutch and Belgian patients with aggressive non-Hodgkin lymphoma treated in 4 European Organization for…
Comparison
At least 6 cycles of doxorubicin-based… vs General population rates
Design
Cohort
Follow-up
median 8.4 years
Authors
Loading...
Supports long-term HF surveillance in NHL survivors; leaves open whether doxorubicin dose or cardioprotection modifies risk.
Cohort (n=476)
Yes
Does doxorubicin-based chemotherapy for aggressive NHL increase the long-term risk of cardiovascular disease compared to the general population?
Effect estimate: SIR 5.4 (95% CI 4.1-6.9)
Patients treated with doxorubicin-based chemotherapy for aggressive NHL have a significantly increased long-term risk of chronic heart failure and stroke, necessitating life-long monitoring, while their risk of coronary artery disease matches the general population.
E. C. Moser (2005) conducted a cohort in Aggressive non-Hodgkin lymphoma (n=476). Doxorubicin-based chemotherapy vs. General population was evaluated on Chronic heart failure (SIR 5.4, 95% CI 4.1-6.9). Doxorubicin-based chemotherapy for aggressive non-Hodgkin lymphoma markedly increased the long-term risk of chronic heart failure compared to the general population (SIR 5.4; 95% CI 4.1-6.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: